Teriparatide for Severe Osteoporosis

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 294-302

  Cappuzzo, Kimberly A ^a   Delafuente, Jeffrey C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

hPTH (1 34); Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCIUM; PARATHYROID HORMONE[1-34]; PHOSPHORUS; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D;

ARTHRALGIA; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRAGILITY FRACTURE; HEADACHE; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; MEDLINE; NAUSEA; OSTEOPOROSIS; OSTEOSARCOMA; PATIENT COUNSELING; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM; COUNSELING; FEMALE; FRACTURES, BONE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS; TERIPARATIDE;

EID: 1642540157     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D353     Document Type: Review

References (55)

1. Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr Opin Pharmacol 2002;2:338-44.
2. Package insert. Forteo (teriparatide [rDNA origin]) injection. Indianapolis: Eli Lilly, November 2002.
3. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone cell lines. Endocrinology 1995;136:3632-8.
4. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-12.
5. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-46.
6. Tam CS, Heersche JNM, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;110:506-12.
7. Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 1983;112:1000-6.
8. Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.
9. Brommage R, Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP. Daily treatments with human recombinant parathyroid hormone (1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 1999;84:3757-63.
10. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macacafascicularis). Bone 2001;28:150-9.
11. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 2000;11:871-80.
12. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
13. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparafide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
14. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35.
15. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43.
16. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tissue Int 1981;33:349-51.
17. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142:4047-54.
18. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Curr Opin Rheumatol 2002;14:433-40.
19. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
20. Sato M, Vahle J, Schmidt A, Westmore M, Smith S, Rowley E, et al. Abnormal bone architecture and biomechanical properties with near-life-time treatment of rats with PTH. Endocrinology 2002;143:3230-42.
21. Forteo, teriparatide injection, NDA 21-318, Endocrinologic and Metabolic Drugs Advisory Committee briefing document, volume 1. June 15, 2001. Food and Drug Administration. http://63.240.199.20/ohrms/dockets/ac/01/briefing/3761b2_01_lilly.pdf (accessed 2003 May 18).
22. Data on file. Indianapolis: Eli Lilly.
23. Satterwhite J, Melnick K, O'Brien L, Myers SL, Heathman M. Men and postmenopausal women with osteoporosis have similar lumbar spine bone mineral density responses to recombinant human parathyroid hormone (1-34) despite pharmacokinetic and biochemical marker differences (abstract). Arthritis Rheum 2001;44(suppl 9):S255.
24. Bringhurst FR, Segre GV, Lampman GW, Potts JT Jr. Metabolism of parathyroid hormone by Kupffer cells: analysis by reverse-phase high-performance liquid chromatography. Biochemistry 1982;21:4252-8.
25. Goltzman D, Bennett HP, Koutsilieris M, Mitchell J, Rabbani SA, Rouleau MF. Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances. Recent Prog Horm Res 1986;42:665-703.
26. Habener JF, Rosenblatt M, Potts JT Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 1984;64:985-1053.
27. Daugaard H. Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Dan Med Bull 1996;43:203-15.
28. Martin KJ, Hruska KA, Freitag JJ, Klahr S, Slatopolsky E. The peripheral metabolism of parathyroid hormone. N Engl J Med 1979;301:1092-8.
29. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, et al. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999;9:296-306.
30. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
31. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8.
32. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000;27:311-8.
33. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33.
34. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000;11:434-42.
35. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15:944-51.
36. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
37. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31.
38. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.
39. Cosman F, Nieves J, Woelfert L, Gordon S, Shen V, Lindsay R. Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. J Clin Endocrinol Metab 1998;83:788-90.
40. Finkelstein JS, Klibanski A, Schafer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
41. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone -(1-34): a randomized controlled trial. JAMA 1998;280:1067-73.
42. Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int 2002;13:267-77.
43. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002;162:2297-309.
44. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23.
45. Orwoll E, Scheele WH, Clancy AD, Adami S, Syversen U, Diex-Perez A, et al. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone mineral density (abstract). J Bone Miner Res 2001;16(suppl 1):S162.
46. www.drugstore.com (accessed 2003 Dec 18).
47. Horwitz M, Stewart S, Greenspan SL. Editorial: sequential parathyroid hormone/alendronate therapy for osteoporosis-robbing Peter to pay Paul? J Clin Endocrinol Metab 2001;85:2127-8.
48. Finkelstein JS, Hayes A, Rao A, Neer RM. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic men (abstract). J Bone Miner Res 2002;17(suppl 1):S127.
49. Neer R, Hayes A, Rao A, Finkelstein J. Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women (abstract). J Bone Miner Res 2002;17(suppl 1):S135.
50. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003;348:579-80.
51. Black DM, Rosen CJ, Greenspan SL, Ensrud KE, Bilezikian J, McGowan D. PTH and bisphosphonates in the treatment of osteoporosis: design of the PTH and alendronate (PaTH) trial (abstract). J Bone Miner Res 2001;16(suppl):S287.
52. Lilly Forteo risk management program limits launch to 8000 doctors. The Pink Sheet 2001;64(50):7-8.
53. Benson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clin Pharmacol Ther 2003;73:87-94.
54. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
55. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.